MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$219,879K
EPS
-$3.36
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
187,402
General and administrative expense
54,246
Total operating expenses
241,648
Loss from operations
-241,648
Interest income
22,212
Other income (expense), net
-443
Net loss before income taxes
-219,879
Effective tax rate
0
Net loss
-219,879
Net loss attributable to noncontrolling interests
0
Net loss attributable to cullinan
-219,879
Basic EPS
-3.36
Diluted EPS
-3.36
Basic Average Shares
59,050,000
Diluted Average Shares
59,050,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to cullinan-$219,879K Net loss-$219,879K Net loss beforeincome taxes-$219,879K Interest income$22,212K Loss from operations-$241,648K Other income(expense), net-$443K Total operatingexpenses$241,648K Research and development$187,402K General andadministrative expense$54,246K

Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics, Inc. (CGEM)